Back to Authors

Wu, Yuling

https://orcid.org/0000-0002-6922-7452

A5103257563 | I4210150756

Mayo Clinic

AstraZeneca (United States)

Citations 1

Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma

Leukemia & Lymphoma | October 15, 2024 | Volume: 65 | Issue: 12 | Pages: 1789-1800

10.1080/10428194.2024.2373331 | PMID 39404476